ESMO GI

Presentations

Ladiratuzumab vedotin | Gastrointestinal Cancer | Abstract P-228

SGNLVA-005: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Aerodigestive Tract Malignancies (Trial in Progress)